CEO, Saol Therapeutics
Industry Council Co-Chair, Georgia Bio

Dave has lived in Atlanta since 2016, when he became CEO of Saol Therapeutics. Under his leadership, Saol has raised more than $100M in aggregate financings, consummated two strategic divestitures to publicly traded biotech companies and created the infrastructure necessary to pursue product development. These successes led to the creation of a robust pipeline that has delivered Saol’s first FDA approval (LYVISPAH®) and multiple late-stage clinical programs in pain related to osteoarthritis of the knee, spasticity, rare diseases and oncology.

Prior to Saol, Dave held a number of roles with consistently growing responsibility at both Genentech and Corcept Therapeutics. As Vice President of Commercial Operations at Corcept, he was instrumental in the early turnaround of the Korlym® franchise, which has since continued to grow at a rapid pace. His overall experience in the industry is based on a balance of commercial leadership roles and those which have required technical expertise in the areas of product development, manufacturing scale-up, finance and CMC.

Dave holds a Bachelor of Science degree in Engineering from Northwestern University, as well as Master of Science and Master of Business Administration degrees from the Massachusetts Institute of Technology. He completed his post-graduate studies at Stanford University and has performed research at Harvard Medical School and the Broad Institute. Dave has been granted 11 US patents, multiple international patents and has pending patent applications in the fields of pharmaceuticals, drug delivery, medical devices and health technology.